Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma

Journal of Pathology

Volumn 216, Issue 3, 2008, Pages 356-364

  Vermi, W ^a   Lonardi, S ^a   Bosisio, D ^a   Uguccioni, M ^b   Danelon, G ^b   Pileri, S ^c   Fletcher, C ^d   Sozzani, S ^a   Zorzi, F ^e   Arrigoni, G ^f   Doglioni, C ^f   Ponzoni, M ^f   Facchetti, F ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Department of Pathology ^*  (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Chemokines; CXCL13; Follicular dendritic cell sarcoma, Castleman's disease; Lymphoid organs

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; IMMUNOGLOBULIN D; MESSENGER RNA; ONCOPROTEIN; PROTEIN TCL1; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CD4+ T LYMPHOCYTE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY INFILTRATE; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA;

ADOLESCENT; ADULT; AGED; CHEMOKINE CXCL13; DENDRITIC CELLS, FOLLICULAR; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODES; MALE; MIDDLE AGED; PALATINE TONSIL; RECEPTORS, CXCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 55249108731     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2420     Document Type: Article

References (28)

1. Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer 1997;79:294-313.
2. Perez-Ordonez B, Rosai J. Follicular dendritic cell tumor: review of the entity. Semin Diagn Pathol 1998;15:144-154.
3. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, et al. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol 2007;82:725-728.
4. Chan JKC. Proliferative lesions of follicular dendritic cells: an overview, including a detailed account of follicular dendritic cell sarcoma, a neoplasm with many faces and uncommon etiologic associations. Adv Anat Pathol 1997;4:387-411.
5. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41:1-29.
6. Grogg KL, Lae ME, Kurtin PJ, Macon WR. Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms: report of a novel follicular dendritic cell marker and clinicopathologic data on 12 additional follicular dendritic cell tumors and 6 additional interdigitating dendritic cell tumors. Am J Surg Pathol 2004;28:988-998.
7. Imai Y, Maeda K, Yamakawa M, Karube Y, Matsuda M, Dobashi M, et al. Heterogeneity and cellular origin of follicular dendritic cells. Adv Exp Med Biol 1993;329:339-344.
8. Rademakers LH, Schuurman HJ. Ultrastructural heterogeneity of follicular dendritic cells in the human tonsil. Adv Exp Med Biol 1993;329:353-358.
9. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol 1988;5:346-364.
10. Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, Hagemeijer A, Sciot R. Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol 2002;26:662-669.
11. Pauwels P, Dal Cin P, Vlasveld LT, Aleva RM, van Erp WF, Jones D. A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol 2000;24:882-888.
12. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998;391:799-803.
13. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655-660.
14. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996;87:1037-1047.
15. Vissers JL, Hartgers FC, Lindhout E, Figdor CG, Adema GJ. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol 2001;31:1544-1549.
16. Vermi W, Facchetti F, Riboldi E, Heine H, Scutera S, Stornello S, et al. Role of dendritic cell-derived CXCL13 in the pathogenesis of Bartonella henselae B-rich granuloma. Blood 2006;107:454- 462.
17. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, Rolph MS, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 2004;173:68-78.
18. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952-4963.
19. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 2006;19:1101-1107.
20. Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006;30:490-494.
21. Mazzucchelli L, Blaser A, Kappeler A, Scharli P, Laissue JA, Baggiolini M, et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest 1999;104:R49-R54.
22. Mueller SN, Hosiawa-Meagher KA, Konieczny BT, Sullivan BM, Bachmann MF, Locksley RM, et al. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 2007;317:670- 674.
23. Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451:669-680.
24. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000;60:2095-2100.
25. Grogg KL, Macon WR, Kurtin PJ, Nascimento AG. A survey of clusterin and fascin expression in sarcomas and spindle cell neoplasms: strong clusterin immunostaining is highly specific for follicular dendritic cell tumor. Mod Pathol 2005;8:260-266.
26. Yu H, Gibson JA, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol 2007;128:776-782.
27. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003;101:815-821.
28. Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol 2002;119:492-495.